Department of Neurology, The First Affiliated Hospital of China Medical University, Shenyang 110001, People's Republic of China.
Department of Neurology, The First Affiliated Hospital of China Medical University, Shenyang 110001, People's Republic of China.
Neurosci Lett. 2020 Jan 10;715:134609. doi: 10.1016/j.neulet.2019.134609. Epub 2019 Nov 4.
The gender effect in the prevalence of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson disease (PD) remains controversial. Herein, we conducted a meta-analysis to investigate the gender effect among these patients.
PubMed and EMBASE databases were searched to identify the potential related studies published before December 2017. Case-control studies with separated data of sex and mutation status were included in further analyses. We pooled relative risk (RR) using fixed-effect model. The publication bias and sensitivity analyses were also performed.
Sixty-four studies with 32452 patients diagnosed with PD were included. Higher prevalence of female patients with LRRK2-associated PD was observed with a pooled RR of 1.22 (95% CI 1.14-1.30, P<0.001). Further subgroup analyses showed that higher prevalence of female patients was only obtained in G2019S mutation patients (RR = 1.32, 95% CI 1.23-1.43, P<0.001), but not in G2385R variant patients (RR = 1.03, 95% CI 0.91-1.17, P = 0.651). No significant heterogeneity and publication bias were observed in additional analyses.
Higher female prevalence of LRRK2 mutation suggests roles of gender-related risk factors in PD patients, especially who carried G2019S mutation. Contrary to idiopathic PD, no sex difference was observed in prevalence of patients carried G2385R variant.
富含亮氨酸重复激酶 2(LRRK2)相关帕金森病(PD)的性别效应仍存在争议。在此,我们进行了一项荟萃分析,以调查这些患者中的性别效应。
检索 PubMed 和 EMBASE 数据库,以确定 2017 年 12 月前发表的潜在相关研究。纳入了具有性别和突变状态分离数据的病例对照研究进行进一步分析。我们使用固定效应模型汇总相对风险(RR)。还进行了发表偏倚和敏感性分析。
纳入了 64 项研究,共 32452 例 PD 患者。LRRK2 相关 PD 女性患者的患病率较高,汇总 RR 为 1.22(95%CI 1.14-1.30,P<0.001)。进一步的亚组分析表明,仅在 G2019S 突变患者中观察到女性患者的患病率较高(RR=1.32,95%CI 1.23-1.43,P<0.001),而在 G2385R 变异患者中则没有(RR=1.03,95%CI 0.91-1.17,P=0.651)。进一步的分析未观察到明显的异质性和发表偏倚。
LRRK2 突变女性患病率较高提示性别相关危险因素在 PD 患者中起作用,尤其是携带 G2019S 突变的患者。与特发性 PD 不同,携带 G2385R 变异的患者的患病率无性别差异。